AR118083A1 - Inhibidores de enzimas - Google Patents
Inhibidores de enzimasInfo
- Publication number
- AR118083A1 AR118083A1 ARP200100397A ARP200100397A AR118083A1 AR 118083 A1 AR118083 A1 AR 118083A1 AR P200100397 A ARP200100397 A AR P200100397A AR P200100397 A ARP200100397 A AR P200100397A AR 118083 A1 AR118083 A1 AR 118083A1
- Authority
- AR
- Argentina
- Prior art keywords
- halo
- independently selected
- alkyl
- ring
- heterocyclyl
- Prior art date
Links
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 28
- 125000000217 alkyl group Chemical group 0.000 abstract 23
- 125000000623 heterocyclic group Chemical group 0.000 abstract 18
- 125000003118 aryl group Chemical group 0.000 abstract 17
- 125000001424 substituent group Chemical group 0.000 abstract 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 16
- 229910052799 carbon Inorganic materials 0.000 abstract 13
- 125000003545 alkoxy group Chemical group 0.000 abstract 12
- 125000004432 carbon atom Chemical group C* 0.000 abstract 11
- 229910052757 nitrogen Inorganic materials 0.000 abstract 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 10
- 229910052717 sulfur Inorganic materials 0.000 abstract 10
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 6
- 125000004474 heteroalkylene group Chemical group 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 125000004043 oxo group Chemical group O=* 0.000 abstract 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 6
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 4
- 125000006574 non-aromatic ring group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 3
- 150000002430 hydrocarbons Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- -1 alkylb Chemical group 0.000 abstract 2
- 239000004305 biphenyl Chemical group 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 2
- 229930195733 hydrocarbon Natural products 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2019/052358 WO2021032935A1 (en) | 2019-08-21 | 2019-08-21 | Enzyme inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118083A1 true AR118083A1 (es) | 2021-09-15 |
Family
ID=67777358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100397A AR118083A1 (es) | 2019-08-21 | 2020-02-13 | Inhibidores de enzimas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220289727A1 (https=) |
| EP (1) | EP4017850A1 (https=) |
| JP (1) | JP2022545159A (https=) |
| KR (1) | KR20220050925A (https=) |
| CN (1) | CN114258392A (https=) |
| AR (1) | AR118083A1 (https=) |
| AU (1) | AU2020331720A1 (https=) |
| BR (1) | BR112022001390A2 (https=) |
| CA (1) | CA3148028A1 (https=) |
| CO (1) | CO2022000270A2 (https=) |
| IL (1) | IL289778A (https=) |
| MX (1) | MX2022000811A (https=) |
| PH (1) | PH12022550118A1 (https=) |
| TW (1) | TW202115021A (https=) |
| WO (2) | WO2021032935A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021032936A1 (en) * | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| CN119264065A (zh) * | 2023-07-05 | 2025-01-07 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123986A (en) * | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
| AU778393B2 (en) * | 1999-05-12 | 2004-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| GB0518237D0 (en) * | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2137158A4 (en) * | 2007-02-28 | 2012-04-18 | Methylgene Inc | LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS) |
| WO2009147188A1 (en) * | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| WO2012074703A1 (en) * | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators |
| US9352016B2 (en) | 2011-03-09 | 2016-05-31 | Csl Behring Gmbh | Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| US8404859B2 (en) * | 2011-03-16 | 2013-03-26 | Hoffmann-La Roche Inc. | Thiazole and thiophene compounds |
| US20120252853A1 (en) * | 2011-04-01 | 2012-10-04 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
| BR112013026341A2 (pt) * | 2011-04-13 | 2019-09-24 | Merck Sharp & Dohe Corp | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia |
| WO2012144661A1 (en) * | 2011-04-20 | 2012-10-26 | Shionogi & Co., Ltd. | Aromatic heterocyclic derivative having trpv4-inhibiting activity |
| US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| AR088989A1 (es) * | 2011-11-30 | 2014-07-23 | Hoffmann La Roche | Derivados biciclicos de dihidroisoquinolin-1-ona |
| PE20150224A1 (es) * | 2012-05-11 | 2015-03-08 | Abbvie Inc | Inhibidores del nampt |
| GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| EP2999697B1 (en) | 2013-05-23 | 2017-04-19 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
| KR102736869B1 (ko) * | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| US10772881B2 (en) * | 2017-02-27 | 2020-09-15 | Russell Dahl | Quinolines that modulate SERCA and their use for treating disease |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| CN104592204B (zh) * | 2014-12-26 | 2017-05-17 | 华润赛科药业有限责任公司 | 达比加群衍生物及其制备方法和用途 |
| WO2017123518A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
| GB201604647D0 (en) * | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| US10759808B2 (en) * | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| AU2017269256B2 (en) | 2016-05-23 | 2021-02-25 | The Rockefeller University | Aminoacylindazole immunomodulators for treatment of autoimmune diseases |
| US10858319B2 (en) * | 2016-10-03 | 2020-12-08 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
| WO2018093716A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
| EP3541375B1 (en) | 2016-11-18 | 2023-08-23 | Merck Sharp & Dohme LLC | Factor xiia inhibitors |
| EP3716972A4 (en) | 2017-11-29 | 2021-08-25 | The Rockefeller University | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| CN112585119A (zh) * | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
| EP4010333A1 (en) * | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021032936A1 (en) * | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
-
2019
- 2019-08-21 WO PCT/GB2019/052358 patent/WO2021032935A1/en not_active Ceased
- 2019-08-21 EP EP19759702.4A patent/EP4017850A1/en not_active Withdrawn
- 2019-08-21 CN CN201980099443.1A patent/CN114258392A/zh active Pending
-
2020
- 2020-02-13 MX MX2022000811A patent/MX2022000811A/es unknown
- 2020-02-13 KR KR1020227008854A patent/KR20220050925A/ko not_active Withdrawn
- 2020-02-13 PH PH1/2022/550118A patent/PH12022550118A1/en unknown
- 2020-02-13 WO PCT/GB2020/050334 patent/WO2021032938A1/en not_active Ceased
- 2020-02-13 TW TW109104466A patent/TW202115021A/zh unknown
- 2020-02-13 US US17/634,593 patent/US20220289727A1/en active Pending
- 2020-02-13 CA CA3148028A patent/CA3148028A1/en active Pending
- 2020-02-13 AU AU2020331720A patent/AU2020331720A1/en active Pending
- 2020-02-13 JP JP2022503834A patent/JP2022545159A/ja not_active Ceased
- 2020-02-13 BR BR112022001390A patent/BR112022001390A2/pt not_active Application Discontinuation
- 2020-02-13 AR ARP200100397A patent/AR118083A1/es not_active Application Discontinuation
-
2022
- 2022-01-12 IL IL289778A patent/IL289778A/en unknown
- 2022-01-17 CO CONC2022/0000270A patent/CO2022000270A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3148028A1 (en) | 2021-02-25 |
| CO2022000270A2 (es) | 2022-01-28 |
| WO2021032935A1 (en) | 2021-02-25 |
| MX2022000811A (es) | 2022-02-16 |
| AU2020331720A1 (en) | 2022-02-24 |
| CN114258392A (zh) | 2022-03-29 |
| IL289778A (en) | 2022-03-01 |
| JP2022545159A (ja) | 2022-10-26 |
| TW202115021A (zh) | 2021-04-16 |
| PH12022550118A1 (en) | 2022-11-21 |
| BR112022001390A2 (pt) | 2022-03-22 |
| KR20220050925A (ko) | 2022-04-25 |
| US20220289727A1 (en) | 2022-09-15 |
| WO2021032938A1 (en) | 2021-02-25 |
| EP4017850A1 (en) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118083A1 (es) | Inhibidores de enzimas | |
| AR118084A1 (es) | Inhibidores de enzimas | |
| AR118081A1 (es) | Inhibidores de enzimas | |
| AR118082A1 (es) | Inhibidores de enzimas | |
| ES2585330T3 (es) | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR112529A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR103833A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR118085A1 (es) | Inhibidores de enzimas | |
| AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR117398A1 (es) | Inhibidores de la señalización mediada por tirosina cinasa 2 | |
| AR105122A1 (es) | INHIBIDORES DE METALO-b-LACTAMASA | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| AR112804A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos | |
| AR114828A1 (es) | Compuestos de pteridinona y sus usos | |
| AR107010A1 (es) | Derivados de piperidina puenteados | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR110122A1 (es) | Fenoxitriazoles | |
| AR117472A1 (es) | Inhibidores de tienopiridina de ripk2 | |
| AR117539A1 (es) | INHIBIDORES DE TGF-bR1 (ALK5) ÚTILES PARA TRATAR TRASTORNOS DE PROLIFERACIÓN CELULAR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |